Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment

Study demonstrates that Smac mimetic LCL161 can overcome vincristine resistance in relapsed neuroblastoma by targeting elevated IAP proteins. Paired cell lines from diagnosis and relapse showed increased cIAP-1 and XIAP expression correlating with vincristine resistance, which LCL161 successfully reversed, suggesting a promising therapeutic strategy for resistant disease.